{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:54:38Z","timestamp":1787003678750,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cystic diseases, especially autosomal dominant polycystic kidney disease (ADPKD; incidence approx. 1\/1000), are a leading cause of renal failure, caused by appearance and growth of renal cysts that can lead to renal failure in middle age. Most ADPKD cases are caused by mutations in\n                    <jats:italic>PKD1<\/jats:italic>\n                    or\n                    <jats:italic>PKD2<\/jats:italic>\n                    , encoding polycystin-1 (PC1) and polycystin-2 (PC2). PC1 is a mechanosensor that controls PC2, a Ca\n                    <jats:sup>2+<\/jats:sup>\n                    -permeable cation channel that, by regulating cytoplasmic Ca\n                    <jats:sup>2+<\/jats:sup>\n                    , prevents adenylyl cyclase producing cyst-promoting concentrations of cAMP. In other systems, there is evidence that PC2 interacts with TRPM3. We therefore examined the effect of pharmacological activators and inhibitors of TRPM3 on cyst formation in cultured mouse kidney rudiments exposed to a range of concentrations of forskolin, a cAMP-elevating drug commonly used experimentally to induce cysts in cultured kidneys. We found that TRPM3 inhibitors (isosakuranetin, primidone, diclofenac) increased cyst formation, while TRPM3 activators (CIM0216 and nifedipine) greatly reduced cyst formation and reduced the sensitivity of kidneys to forskolin. These preclinical, in-vitro data suggest that TRPM3 may be a promising target in ADPKD management.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-89200-z","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T02:01:31Z","timestamp":1738980091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting TRPM3 as a potential therapeutic approach for autosomal dominant polycystic kidney disease"],"prefix":"10.1038","volume":"15","author":[{"given":"H\u00fcseyin","family":"G\u00fcl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"89200_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i679","author":"RJ Simms","year":"2016","unstructured":"Simms, R. J. Autosomal dominant polycystic kidney disease. BMJ https:\/\/doi.org\/10.1136\/bmj.i679 (2016).","journal-title":"BMJ"},{"issue":"16","key":"89200_CR2","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1056\/NEJM199010183231601","volume":"323","author":"PS Parfrey","year":"1990","unstructured":"Parfrey, P. S. et al. The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N. Engl. J. Med. 323(16), 1085\u20131090 (1990).","journal-title":"N. Engl. J. Med."},{"key":"89200_CR3","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone","year":"2003","unstructured":"Gattone, V. H., Wang, X., Harris, P. C. & Torres, V. E. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat. Med. 9, 1323\u20131326 (2003).","journal-title":"Nat. Med."},{"key":"89200_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1681\/ASN.2013040398","volume":"25","author":"VE Torres","year":"2014","unstructured":"Torres, V. E. & Harris, P. C. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J. Am. Soc. Nephrol. 25, 18\u201332 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"89200_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40620-021-01062-6","volume":"35","author":"I Capuano","year":"2022","unstructured":"Capuano, I., Buonanno, P., Riccio, E., Amicone, M. & Pisani, A. Therapeutic advances in ADPKD: The future awaits. J. Nephrol. 35, 397\u2013415 (2022).","journal-title":"J. Nephrol."},{"key":"89200_CR6","unstructured":"Haldeman-Englert, C. R., Jewett, T., Mulle, J. G., Gambello, M. J., Russo, R. S., Murphy, M. M. & Medin, J. A. GeneReviews\u00ae (1993)."},{"key":"89200_CR7","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1681\/ASN.2015050583","volume":"27","author":"CM Heyer","year":"2016","unstructured":"Heyer, C. M. et al. Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 27, 2872\u20132884 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"89200_CR8","doi-asserted-by":"publisher","first-page":"e0289778","DOI":"10.1371\/journal.pone.0289778","volume":"18","author":"CC Lin","year":"2023","unstructured":"Lin, C. C. et al. In vivo Polycystin-1 interactome using a novel Pkd1 knock-in mouse model. Plos one 18(8), e0289778 (2023).","journal-title":"Plos one"},{"key":"89200_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-physiol-031522-084334","volume":"85","author":"O Esarte Palomero","year":"2023","unstructured":"Esarte Palomero, O., Larmore, M. & DeCaen, P. G. Polycystin channel complexes. Annu. Rev. Physiol. 85, 425\u2013448 (2023).","journal-title":"Annu. Rev. Physiol."},{"key":"89200_CR10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.biochi.2022.06.010","volume":"201","author":"PF Tian","year":"2022","unstructured":"Tian, P. F., Sun, M. M., Hu, X. Y., Du, J. & He, W. TRPP2 ion channels: the roles in various subcellular locations. Biochimie 201, 116\u2013127 (2022).","journal-title":"Biochimie"},{"issue":"2","key":"89200_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/ng1076","volume":"33","author":"SM Nauli","year":"2003","unstructured":"Nauli, S. M. et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat. Genet. 33(2), 129\u2013137 (2003).","journal-title":"Nat. Genet."},{"key":"89200_CR12","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1681\/ASN.2006030295","volume":"17","author":"BS Magenheimer","year":"2006","unstructured":"Magenheimer, B. S. et al. Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to camp stimulation with cystic fibrosis transmembrane conductance regulator\/Na+, K+, 2Cl\u2212 co-transporter\u2013dependent cystic dilation. J. Am. Soc. Nephrol. 17, 3424\u20133437 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"89200_CR13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ki.2008.246","volume":"74","author":"M Albaqumi","year":"2008","unstructured":"Albaqumi, M. et al. KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int. 74, 740\u2013749 (2008).","journal-title":"Kidney Int."},{"key":"89200_CR14","doi-asserted-by":"publisher","first-page":"11513","DOI":"10.1074\/jbc.RA118.001846","volume":"293","author":"MK Yanda","year":"2018","unstructured":"Yanda, M. K., Liu, Q. & Cebotaru, L. A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector. J. Biol. Chem. 293, 11513\u201311526 (2018).","journal-title":"J. Biol. Chem."},{"key":"89200_CR15","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.bbrc.2020.06.141","volume":"529","author":"T Shimizu","year":"2020","unstructured":"Shimizu, T. et al. A novel ADPKD model using kidney organoids derived from disease-specific human iPSCs. Biochem. Biophys. Res. Commun. 529, 1186\u20131194 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"89200_CR16","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1681\/ASN.V1171179","volume":"11","author":"K Hanaoka","year":"2000","unstructured":"Hanaoka, K. & Guggino, W. B. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J. Am. Soc. Nephrol. 11(7), 1179\u20131187 (2000).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"39","key":"89200_CR17","doi-asserted-by":"publisher","first-page":"40419","DOI":"10.1074\/jbc.M405079200","volume":"279","author":"T Yamaguchi","year":"2004","unstructured":"Yamaguchi, T. et al. Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J. Biol. Chem. 279(39), 40419\u201340430 (2004).","journal-title":"J. Biol. Chem."},{"issue":"25","key":"89200_CR18","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367(25), 2407\u20132418 (2012).","journal-title":"N. Engl. J. Med."},{"key":"89200_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1053\/j.akdh.2023.01.003","volume":"30","author":"JX Zhou","year":"2023","unstructured":"Zhou, J. X. & Torres, V. E. Autosomal dominant polycystic kidney disease therapies on the horizon. Adv. Kidney Dis. Health 30, 245\u2013260 (2023).","journal-title":"Adv. Kidney Dis. Health"},{"key":"89200_CR20","doi-asserted-by":"publisher","first-page":"e0214053","DOI":"10.1371\/journal.pone.0214053","volume":"14","author":"SJ Kleene","year":"2019","unstructured":"Kleene, S. J. et al. The TRPP2-dependent channel of renal primary cilia also requires TRPM3. PLoS One 14, e0214053 (2019).","journal-title":"PLoS One"},{"key":"89200_CR21","doi-asserted-by":"publisher","first-page":"35507","DOI":"10.1074\/jbc.M109.060228","volume":"284","author":"T Kobori","year":"2009","unstructured":"Kobori, T., Smith, G. D., Sandford, R. & Edwardson, J. M. The transient receptor potential channels TRPP2 and TRPC1 form a heterotetramer with a 2:2 stoichiometry and an alternating subunit arrangement. J. Biol. Chem. 284, 35507\u201335513 (2009).","journal-title":"J. Biol. Chem."},{"issue":"6406","key":"89200_CR22","doi-asserted-by":"publisher","first-page":"eaat9819","DOI":"10.1126\/science.aat9819","volume":"361","author":"Q Su","year":"2018","unstructured":"Su, Q. et al. Structure of the human PKD1-PKD2 complex. Science 361(6406), eaat9819 (2018).","journal-title":"Science"},{"key":"89200_CR23","doi-asserted-by":"publisher","first-page":"20890","DOI":"10.1074\/jbc.M211232200","volume":"278","author":"N Lee","year":"2003","unstructured":"Lee, N. et al. Expression and characterization of human transient receptor potential melastatin 3 (hTRPM3). J. Biol. Chem. 278, 20890\u201320897 (2003).","journal-title":"J. Biol. Chem."},{"key":"89200_CR24","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1172\/JCI41531","volume":"120","author":"S Qin","year":"2010","unstructured":"Qin, S. et al. Failure to ubiquitinate c-met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease. J. Clin. Invest. 120, 3617\u20133628 (2010).","journal-title":"J. Clin. Invest."},{"key":"89200_CR25","doi-asserted-by":"publisher","first-page":"F1234","DOI":"10.1152\/ajprenal.00356.2011","volume":"302","author":"H Zhou","year":"2012","unstructured":"Zhou, H. et al. Ginkgolide B inhibits renal cyst development in in vitro and in vivo cyst models. Am. J. Physiol. Renal Physiol. 302, F1234\u2013F1242 (2012).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"89200_CR26","doi-asserted-by":"publisher","first-page":"e57797","DOI":"10.1371\/journal.pone.0057797","volume":"8","author":"C Anders","year":"2013","unstructured":"Anders, C., Ashton, N., Ranjzad, P., Dilworth, M. R. & Woolf, A. S. Ex vivo modeling of chemical synergy in prenatal kidney cystogenesis. PLoS One 8, e57797 (2013).","journal-title":"PLoS One"},{"key":"89200_CR27","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1681\/ASN.2013070735","volume":"25","author":"PV Tran","year":"2014","unstructured":"Tran, P. V. et al. Downregulating hedgehog signaling reduces renal cystogenic potential of mouse models. J. Am. Soc. Nephrol. 25, 2201\u20132212 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"89200_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1681\/ASN.2013030209","volume":"25","author":"B Buchholz","year":"2014","unstructured":"Buchholz, B. et al. Hypoxia-inducible factor-1\u03b1 causes renal cyst expansion through calcium-activated chloride secretion. J. Am. Soc. Nephrol. 25, 465\u2013474 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"89200_CR29","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1681\/ASN.2007070828","volume":"19","author":"B Yang","year":"2008","unstructured":"Yang, B., Sonawane, N. D., Zhao, D., Somlo, S. & Verkman, A. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 19, 1300\u20131310 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"89200_CR30","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1021\/jm960191+","volume":"39","author":"JD Robbins","year":"1996","unstructured":"Robbins, J. D., Boring, D. L., Tang, W. J., Shank, R. & Seamon, K. B. Forskolin carbamates: Binding and activation studies with type I adenylyl cyclase. J. Med. Chem. 39, 2745\u20132752 (1996).","journal-title":"J. Med. Chem."},{"key":"89200_CR31","doi-asserted-by":"publisher","first-page":"D1282","DOI":"10.1093\/nar\/gkab1010","volume":"50","author":"SD Harding","year":"2022","unstructured":"Harding, S. D. et al. The IUPHAR\/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials. Nucl. Acids Res. 50, D1282\u2013D1294 (2022).","journal-title":"Nucl. Acids Res."},{"key":"89200_CR32","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1124\/mol.113.086843","volume":"84","author":"I Straub","year":"2013","unstructured":"Straub, I. et al. Flavanones that selectively inhibit TRPM3 attenuate thermal nociception in vivo. Mol. Pharmacol. 84, 736\u2013750 (2013).","journal-title":"Mol. Pharmacol."},{"key":"89200_CR33","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/j.pain.0000000000000846","volume":"158","author":"U Kr\u00fcgel","year":"2017","unstructured":"Kr\u00fcgel, U., Straub, I., Beckmann, H. & Schaefer, M. Primidone inhibits TRPM3 and attenuates thermal nociception in vivo. Pain 158, 856\u2013867 (2017).","journal-title":"Pain"},{"key":"89200_CR34","doi-asserted-by":"publisher","first-page":"11693","DOI":"10.1073\/pnas.90.24.11693","volume":"90","author":"JA Mitchell","year":"1993","unstructured":"Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J. & Vane, J. R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 90, 11693\u201311697 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"89200_CR35","doi-asserted-by":"publisher","first-page":"e00232","DOI":"10.1002\/prp2.232","volume":"4","author":"H Suzuki","year":"2016","unstructured":"Suzuki, H. et al. Diclofenac, a nonsteroidal anti-inflammatory drug, is an antagonist of human TRPM 3 isoforms. Pharmacol. Res. Perspect. 4, e00232 (2016).","journal-title":"Pharmacol. Res. Perspect."},{"key":"89200_CR36","doi-asserted-by":"publisher","first-page":"E1363","DOI":"10.1073\/pnas.1419845112","volume":"112","author":"K Held","year":"2015","unstructured":"Held, K. et al. Activation of TRPM3 by a potent synthetic ligand reveals a role in peptide release. Proc. Natl. Acad. Sci. USA 112, E1363\u2013E1372 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"89200_CR37","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1096\/fj.15-281576","volume":"30","author":"K Uchida","year":"2016","unstructured":"Uchida, K. et al. Stimulation-dependent gating of TRPM3 channel in planar lipid bilayers. FASEB J. 30, 1306 (2016).","journal-title":"FASEB J."},{"key":"89200_CR38","doi-asserted-by":"publisher","first-page":"e27034","DOI":"10.4161\/psb.27034","volume":"8","author":"MB Price","year":"2013","unstructured":"Price, M. B., Kong, D. & Okumoto, S. Inter-subunit interactions between glutamate-like receptors in Arabidopsis. Plant Signal. Behav. 8, e27034 (2013).","journal-title":"Plant Signal. Behav."},{"issue":"7","key":"89200_CR39","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1074\/jbc.M808786200","volume":"284","author":"MM Schnitzler","year":"2009","unstructured":"Schnitzler, M. M. et al. Mutation of histidine 105 in the T1 domain of the potassium channel Kv2.1 disrupts heteromerization with Kv6.3 and Kv6.4. J. Biol. Chem. 284(7), 4695\u20134704 (2009).","journal-title":"J. Biol. Chem."},{"key":"89200_CR40","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2174\/1570159X19666211104145727","volume":"20","author":"V Fern\u00e1ndez-Due\u00f1as","year":"2022","unstructured":"Fern\u00e1ndez-Due\u00f1as, V. et al. Overcoming the challenges of detecting GPCR oligomerization in the brain. Curr. Neuropharmacol. 20, 1035 (2022).","journal-title":"Curr. Neuropharmacol."},{"key":"89200_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0143-4160(90)90060-8","volume":"11","author":"MW Roe","year":"1990","unstructured":"Roe, M. W., Lemasters, J. J. & Herman, B. Assessment of Fura-2 for measurements of cytosolic free calcium. Cell Calcium 11, 63\u201373 (1990).","journal-title":"Cell Calcium"},{"key":"89200_CR42","doi-asserted-by":"publisher","first-page":"902290","DOI":"10.3389\/fphar.2022.902290","volume":"13","author":"W Liu","year":"2022","unstructured":"Liu, W., Liu, C., Ren, P. G., Chu, J. & Wang, L. An improved genetically encoded fluorescent cAMP indicator for sensitive cAMP imaging and fast DRUG screening. Front. Pharmacol. 13, 902290 (2022).","journal-title":"Front. Pharmacol."},{"key":"89200_CR43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.stem.2013.11.010","volume":"14","author":"A Taguchi","year":"2014","unstructured":"Taguchi, A. et al. Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. Cell Stem Cell 14, 53\u201367 (2014).","journal-title":"Cell Stem Cell"},{"key":"89200_CR44","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/nbt.3392","volume":"33","author":"R Morizane","year":"2015","unstructured":"Morizane, R. et al. Nephron organoids derived from human pluripotent stem cells model kidney development and injury. Nat. Biotechnol. 33, 1193\u20131200 (2015).","journal-title":"Nat. Biotechnol."},{"issue":"7574","key":"89200_CR45","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature15695","volume":"526","author":"M Takasato","year":"2015","unstructured":"Takasato, M. et al. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature 526(7574), 564\u2013568 (2015).","journal-title":"Nature"},{"issue":"1","key":"89200_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.stem.2023.12.003","volume":"31","author":"M Liu","year":"2024","unstructured":"Liu, M. et al. Kidney organoid models reveal cilium-autophagy metabolic axis as a therapeutic target for PKD both in vitro and in vivo. Cell Stem Cell. 31(1), 52\u201370 (2024).","journal-title":"Cell Stem Cell."},{"key":"89200_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/bs.mcb.2019.05.008","volume":"153","author":"M Sharma","year":"2019","unstructured":"Sharma, M., Reif, G. A. & Wallace, D. P. In vitro cyst formation of ADPKD cells. Methods Cell Biol. 153, 93\u2013111 (2019).","journal-title":"Methods Cell Biol."},{"issue":"12","key":"89200_CR48","doi-asserted-by":"publisher","first-page":"113431","DOI":"10.1016\/j.celrep.2023.113431","volume":"42","author":"SI Mae","year":"2023","unstructured":"Mae, S. I. et al. Human iPSC-derived renal collecting duct organoid model cystogenesis in ADPKD. Cell Rep. 42(12), 113431 (2023).","journal-title":"Cell Rep."},{"issue":"11","key":"89200_CR49","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1038\/s41588-022-01202-z","volume":"54","author":"Y Xu","year":"2022","unstructured":"Xu, Y. et al. Adult human kidney organoids originate from CD24+ cells and represent an advanced model for adult polycystic kidney disease. Nat. Genet. 54(11), 1690\u20131701 (2022).","journal-title":"Nat. Genet."},{"issue":"1","key":"89200_CR50","doi-asserted-by":"publisher","first-page":"16532","DOI":"10.1038\/s41598-021-95986-5","volume":"11","author":"Y Shamshirgaran","year":"2021","unstructured":"Shamshirgaran, Y. et al. Rapid target validation in a Cas9-inducible hiPSC derived kidney model. Sci. Rep. 11(1), 16532 (2021).","journal-title":"Sci. Rep."},{"key":"89200_CR51","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","volume":"393","author":"E Cornec-Le Gall","year":"2019","unstructured":"Cornec-Le Gall, E., Alam, A. & Perrone, R. D. Autosomal dominant polycystic kidney disease. Lancet 393, 919\u2013935 (2019).","journal-title":"Lancet"},{"issue":"9","key":"89200_CR52","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1681\/ASN.2015050583","volume":"27","author":"CM Heyer","year":"2016","unstructured":"Heyer, C. M. et al. Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 27(9), 2872\u20132884 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"89200_CR53","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1538\/expanim.61.477","volume":"61","author":"S Nagao","year":"2012","unstructured":"Nagao, S., Kugita, M., Yoshihara, D. & Yamaguchi, T. Animal models for human polycystic kidney disease. Exp. Anim. 61, 477\u2013488 (2012).","journal-title":"Exp. Anim."},{"key":"89200_CR54","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrneph.2014.137","volume":"10","author":"H Happe","year":"2014","unstructured":"Happe, H. & Peters, D. J. Translational research in ADPKD: lessons from animal models. Nat. Rev. Nephrol. 10, 587\u2013601 (2014).","journal-title":"Nat. Rev. Nephrol."},{"issue":"4","key":"89200_CR55","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.34067\/KID.0000000000000209","volume":"360","author":"CJ Sieben","year":"2023","unstructured":"Sieben, C. J. & Harris, P. C. Experimental models of polycystic kidney disease: applications and therapeutic testing. Kidney 360(4), 1155\u20131173 (2023).","journal-title":"Kidney"},{"issue":"6","key":"89200_CR56","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1681\/ASN.2006010052","volume":"18","author":"AK Ahrabi","year":"2007","unstructured":"Ahrabi, A. K. et al. PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice. J. Am. Soc. Nephrol. 18(6), 1740\u20131753 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"24","key":"89200_CR57","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1093\/hmg\/ddm299","volume":"16","author":"IS Lantinga-van Leeuwen","year":"2007","unstructured":"Lantinga-van Leeuwen, I. S. et al. Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice. Hum. Mol. Genet. 16(24), 3188\u20133196 (2007).","journal-title":"Hum. Mol. Genet."},{"issue":"12","key":"89200_CR58","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41588-021-00946-4","volume":"53","author":"K Dong","year":"2021","unstructured":"Dong, K. et al. Renal plasticity revealed through reversal of polycystic kidney disease in mice. Nat. Genet. 53(12), 1649\u20131663 (2021).","journal-title":"Nat. Genet."}],"updated-by":[{"DOI":"10.1038\/s41598-025-09561-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89200-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89200-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89200-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T05:39:47Z","timestamp":1757137187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89200-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89200"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89200-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-025-09561-3","URL":"https:\/\/doi.org\/10.1038\/s41598-025-09561-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4714"}}